ArticleJTCVS open2025
Segmentectomy versus lobectomy for centrally located small-sized and radiologically pure-solid non-small cell lung cancer.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study).Annals of surgical oncology · 2026Article
- Oncologic outcomes of segmentectomy in c-stage I non-small cell lung cancer with visceral pleural invasion: A multicenter retrospective study.JTCVS open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to compare segmentectomy and lobectomy in centrally located, small-sized (≤2 cm), radiologically pure-solid cN0 non-small cell lung cancer, particularly focusing on hypermetabolic tumors, because the feasibility of segmentectomy for centrally located, more aggressive non-small cell lung cancer remains uncertain. Methods: We retrospectively evaluated 214 patients with centrally located small-sized (≤2 cm) and radiologically pure-solid cN0 non-small cell lung cancer who underwent segmentectomy (n = 82) or lobectomy (n = 132) at 3 institutions. Tumors located in the inner two-thirds of the pulmonary parenchyma were defined as centrally located. Propensity score matching was used to balance the baseline characteristics. Hypermetabolic tumors were identified based on the maximum standard uptake value, with high-grade malignancy indicated by the presence of pleural or lymphovascular invasion, or lymph node metastasis, as predicted by receiver operating characteristic curve. Results: High-grade malignancy was confirmed in 115 patients (53.7%). After propensity score matching, no significant differences in clinical baseline characteristics were found among the 66 matched patients. Overall survival and recurrence-free survival did not significantly differ between segmentectomy and lobectomy groups ( Conclusions: Segmentectomy may be a feasible alternative to lobectomy in patients with centrally located, small-sized, and radiologically pure-solid non-small cell lung cancer, even in those with high-grade malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.